Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Satoshi Watanabe

Showing results (781-790 of 817) with videos related to

Pageof 82
Sort By:
Cancer Letters|February 11, 2024
AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cellsKenji Morimoto, Tadaaki Yamada, Soichi Hirai, et al.
Hepatology Communications|January 13, 2021
Assessment of Adenosine Triphosphatase Phospholipid Transporting 8B1 (ATP8B1) Function in Patients With Cholestasis With ATP8B1 Deficiency by Using Peripheral Blood Monocyte-Derived MacrophagesAyumu Mizutani, Yusuke Sabu, Sotaro Naoi, et al.
NPJ Precision Oncology|January 19, 2022
HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal featuresKeiko Tanimura, Tadaaki Yamada, Koutaroh Okada, et al.
Lung Cancer (Amsterdam, Netherlands)|August 11, 2022
Real-world outcomes of chemotherapy for lung cancer patients undergoing hemodialysis: A multicenter retrospective cohort study (NEJ-042)Yuji Minegishi, Tomoe Akagami, Makoto Arai, et al.
Cancers|January 8, 2023
Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory <i>ALK</i>-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501)Satoshi Watanabe, Kazuko Sakai, Naoya Matsumoto, et al.
The Lancet. Oncology|April 13, 2019
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trialHaruhiro Saito, Tatsuro Fukuhara, Naoki Furuya, et al.
Cancer Immunology, Immunotherapy : CII|March 5, 2026
Nintedanib enhances the antitumor efficacy of pd-1 blockade, potentially through inhibition of myeloid-derived suppressor cells and cancer-associated fibroblastsRyo Suzuki, Satoshi Watanabe, Kunihiro Shono, et al.
Aging Cell|July 29, 2020
Impaired phagocytic function in CX3CR1<sup>+</sup> tissue-resident skeletal muscle macrophages prevents muscle recovery after influenza A virus-induced pneumonia in old miceConstance E Runyan, Lynn C Welch, Emilia Lecuona, et al.
The Lancet. Respiratory Medicine|August 29, 2021
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trialYosuke Kawashima, Tatsuro Fukuhara, Haruhiro Saito, et al.
Cell|August 21, 2025
Adenosine kinase and ADAL coordinate detoxification of modified adenosines to safeguard metabolismAkiko Ogawa, Satoshi Watanabe, Iuliia Ozerova, et al.
Pageof 82

Showing results (781-790 of 817) with videos related to

Sort By:
Pageof 82
Cancer Letters|February 11, 2024
AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cellsKenji Morimoto, Tadaaki Yamada, Soichi Hirai, et al.
Hepatology Communications|January 13, 2021
Assessment of Adenosine Triphosphatase Phospholipid Transporting 8B1 (ATP8B1) Function in Patients With Cholestasis With ATP8B1 Deficiency by Using Peripheral Blood Monocyte-Derived MacrophagesAyumu Mizutani, Yusuke Sabu, Sotaro Naoi, et al.
NPJ Precision Oncology|January 19, 2022
HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal featuresKeiko Tanimura, Tadaaki Yamada, Koutaroh Okada, et al.
Lung Cancer (Amsterdam, Netherlands)|August 11, 2022
Real-world outcomes of chemotherapy for lung cancer patients undergoing hemodialysis: A multicenter retrospective cohort study (NEJ-042)Yuji Minegishi, Tomoe Akagami, Makoto Arai, et al.
Cancers|January 8, 2023
Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory <i>ALK</i>-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501)Satoshi Watanabe, Kazuko Sakai, Naoya Matsumoto, et al.
The Lancet. Oncology|April 13, 2019
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trialHaruhiro Saito, Tatsuro Fukuhara, Naoki Furuya, et al.
Cancer Immunology, Immunotherapy : CII|March 5, 2026
Nintedanib enhances the antitumor efficacy of pd-1 blockade, potentially through inhibition of myeloid-derived suppressor cells and cancer-associated fibroblastsRyo Suzuki, Satoshi Watanabe, Kunihiro Shono, et al.
Aging Cell|July 29, 2020
Impaired phagocytic function in CX3CR1<sup>+</sup> tissue-resident skeletal muscle macrophages prevents muscle recovery after influenza A virus-induced pneumonia in old miceConstance E Runyan, Lynn C Welch, Emilia Lecuona, et al.
The Lancet. Respiratory Medicine|August 29, 2021
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trialYosuke Kawashima, Tatsuro Fukuhara, Haruhiro Saito, et al.
Cell|August 21, 2025
Adenosine kinase and ADAL coordinate detoxification of modified adenosines to safeguard metabolismAkiko Ogawa, Satoshi Watanabe, Iuliia Ozerova, et al.
Pageof 82